Difference between revisions of "Epithelioid sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")
 
m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''")
 
(30 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
{| class="wikitable" style="text-align:center; width:50%;"
+
<span id="BackToTop"></span>
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
|-
+
[[#top|Back to Top]]
−
|style="background-color:#F0F0F0"|[[File:Elizabethdavis2.jpg|frameless|upright=0.3|center]]
+
</div>
−
|<big>[[User:Elizabethdavis|Elizabeth J. Davis, MD]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/ejdavis25 ejdavis25]
+
{{#lst:Editorial board transclusions|sarcoma}}
−
|-
+
Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens.
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 12: Line 11:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 +
==NCCN==
 +
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma].''
 
=All lines of therapy=
 
=All lines of therapy=
 
==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}==
 
==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}==
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
 
===Regimen {{#subobject:43c238|Variant=1}}===
 
===Regimen {{#subobject:43c238|Variant=1}}===
 
{| class="wikitable" style="color:white; background-color:#404040"
 
{| class="wikitable" style="color:white; background-color:#404040"
Line 23: Line 23:
 
|-
 
|-
 
|}
 
|}
−
{| class="wikitable" style="width: 50%; text-align:center;"  
+
{| class="wikitable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1016/s1470-2045(20)30451-4 Gounder et al. 2020 (EZH-202)]
 +
<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
 +
|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-252-1 <span style="color:white;">ESMO-MCBS (1)</span>]'''
 
|-
 
|-
−
|[https://clinicaltrials.gov/ct2/show/NCT02601950 See note]
+
|} -->
−
| style="background-color:#91cf61" |Phase II (RT)
+
|2015-2017
 +
| style="background-color:#91cf61" |Phase 2 (RT)
 
|-
 
|-
 
|}
 
|}
−
''Note: this study has not yet been published, to our knowledge.''
+
<div class="toccolours" style="background-color:#fdcdac">
−
====Chemotherapy====
+
====Biomarker eligibility criteria====
−
*[[Tazemetostat (Tazverik)]] 800 mg PO twice per day
+
One or both of the following:
 +
*Loss of INI1 expression by IHC
 +
*Biallelic SMARCB1 alterations
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 +
*[[Tazemetostat (Tazverik)]] 800 mg PO twice per day on days 1 to 28
  
−
'''Continued indefinitely'''
+
'''28-day cycles'''
 +
</div></div>
  
 
===References===
 
===References===
−
# '''EZH-202:''' [https://clinicaltrials.gov/ct2/show/NCT02601950 CT.gov]
+
<!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma ([https://clinicaltrials.gov/study/NCT02601950 NCT02601950]). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/study/NCT02601950 NCT02601950] CT.gov] -->
 +
# '''EZH-202:''' Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. [https://doi.org/10.1016/s1470-2045(20)30451-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33035459/ PubMed] [https://clinicaltrials.gov/study/NCT02601950 NCT02601950]
  
 
[[Category:Epithelioid sarcoma regimens]]
 
[[Category:Epithelioid sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Soft tissue sarcomas]]
 
[[Category:Soft tissue sarcomas]]
−
[[Category:Pediatric cancers]]
+
[[Category:Pediatric solid tumors]]

Latest revision as of 23:40, 15 July 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
1 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

All lines of therapy

Tazemetostat monotherapy

Regimen

FDA-recommended dose
Study Dates of enrollment Evidence
Gounder et al. 2020 (EZH-202) 2015-2017 Phase 2 (RT)

Biomarker eligibility criteria

One or both of the following:

  • Loss of INI1 expression by IHC
  • Biallelic SMARCB1 alterations

Targeted therapy

28-day cycles

References

  1. EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02601950
Retrieved from "https://hemonc.org/w/index.php?title=Epithelioid_sarcoma&oldid=89844"